Literature DB >> 28281493

Use of resting-state fMRI in planning epilepsy surgery.

Sharon Chiang1, Zulfi Haneef2, John M Stern3, Jerome Engel4.   

Abstract

Epileptic seizures result from abnormal neuronal excitability and synchronization, affecting 0.5-1% of the population worldwide. Although anti-seizure drugs are often effective, a significant number of patients with epilepsy continue to experience refractory seizures and are candidates for surgical resection. Whereas standard presurgical evaluation has relied on intracranial electroencephalography (icEEG) and direct cortical stimulation to identify epileptogenic tissue and areas of cortex for which resection would produce clinical deficits, the invasive nature and limited spatial extent of icEEG has led to the investigation of less invasive imaging modalities as adjunctive tools in the presurgical workup. In the past few decades, functional connectivity MRI has emerged as a promising approach for presurgical mapping, leading to a surge in the number of proposed methods and biomarkers for identifying epileptogenic tissue. This review focuses on recent advances in the use of functional connectivity MRI toward its application for presurgical planning, including epilepsy localization and eloquent cortex mapping.

Entities:  

Mesh:

Year:  2017        PMID: 28281493     DOI: 10.4103/neuroindia.NI_823_16

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  2 in total

1.  A Hierarchical Bayesian Model for the Identification of PET Markers Associated to the Prediction of Surgical Outcome after Anterior Temporal Lobe Resection.

Authors:  Sharon Chiang; Michele Guindani; Hsiang J Yeh; Sandra Dewar; Zulfi Haneef; John M Stern; Marina Vannucci
Journal:  Front Neurosci       Date:  2017-12-05       Impact factor: 4.677

2.  Optimization of surgical intervention outside the epileptogenic zone in the Virtual Epileptic Patient (VEP).

Authors:  Sora An; Fabrice Bartolomei; Maxime Guye; Viktor Jirsa
Journal:  PLoS Comput Biol       Date:  2019-06-26       Impact factor: 4.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.